Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician
Tóm tắt
Today the pharmacological possibilities of treating cancer are expanding and as a result, life expectancy is increasing against the background of chemotherapy and supportive treatment. In the conditions of successful antitumor treatment, complications associated with its toxic effect on healthy tissues and organs began to come to the fore. Anthracycline cardiomyopathy was the first serious cardiovascular complication to draw the attention of oncologists and cardiologists around the world. Anthracycline drugs such as doxorubicin, epirubicin, idarubicin are still widely used in oncological practice to treat a wide range of solid and hematological malignancies. Doxorubicin-induced cardiomyopathy is closely associated with an increase in oxidative stress, as evidenced by reactive oxygen species (ROS) nduced damage such as lipid peroxidation, and decreased levels of antioxidants. Myofibrillar destruction and dysregulation of intracellular calcium are also important mechanisms, usually associated with doxorubicin-induced cardiotoxicity. Despite the abundance of data on various mechanisms involved in the implementation of doxorubicin-induced cardiotoxicity, a final understanding of the mechanism of the development of doxorubicin cardiomyopathy has not yet been formed. It poses the most significant challenges to the development of new methods of prevention and treatment, as well as to the unambiguous choice of a specific treatment regimen using the existing pharmacological tools. In order to resolve these issues new models that could reflect the development of the chemotherapy drugs effects are needed. In this review we have summarized and analyzed information on the main existing models of doxorubicin cardiomyopathy using small laboratory animals. In addition, this paper discusses further areas of research devoted to the development and validation of new improved models of doxorubicin cardiomyopathy suitable both for studying the mechanisms of its implementation and for the preclinical drugs effectiveness assessment.
Từ khóa
Tài liệu tham khảo
Abd-Allah, 2002, Protective Effect of Arabic Gum against Cardiotoxicity Induced by Doxorubicin in Mice: A Possible Mechanism of protection, J. Biochem. Mol. Toxicol., 16, 254, 10.1002/jbt.10046
Abushouk, 2017, Cardioprotective Mechanisms of Phytochemicals against Doxorubicin-Induced Cardiotoxicity, Biomed. Pharmacother., 90, 935, 10.1016/j.biopha.2017.04.033
Ahmad, 2017, Folic Acid Ameliorates Celecoxib Cardiotoxicity in a Doxorubicin Heart Failure Rat Model, Pharm. Biol., 55, 1295, 10.1080/13880209.2017.1299768
Allen, 2019, Slow-Release Doxorubicin Pellets Generate Myocardial Cardiotoxic Changes in Mice without Significant Systemic Toxicity, Cardiovasc. Toxicol., 19, 482, 10.1007/s12012-019-09521-0
Aygun, 2019, Cardioprotective Effect of Melatonin and Agomelatine on Doxorubicin-Induced Cardiotoxicity in a Rat Model: an Electrocardiographic, Scintigraphic and Biochemical Study, Bll, 120, 249, 10.4149/bll_2019_045
Aykan, 2020, Bisoprolol and Linagliptin Ameliorated Electrical and Mechanical Isometric Myocardial Contractions in Doxorubicin-Induced Cardiomyopathy in Rats, Pharmacol. Rep., 72, 867, 10.1007/s43440-019-00034-9
Bai, 2019, Genistein Protects against Doxorubicin‐induced Cardiotoxicity through Nrf‐2/HO‐1 Signaling in Mice Model, Environ. Toxicol., 34, 645, 10.1002/tox.22730
Barış, 2019, Protective Effect of Taurine against Doxorubicin-Induced Cardiotoxicity in Rats: Echocardiographical and Histological Findings, Amino Acids, 51, 1649, 10.1007/s00726-019-02801-7
Bertazzoli, 1979, Quantitative Experimental Evaluation of Adriamycin Cardiotoxicity in the Mouse, Cancer Treat. Rep., 63, 1877
Cappetta, 2017, Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity, Oxidative Med. Cell Longevity, 2017, 1, 10.1155/2017/1521020
Cappetta, 2017, Effects of Ranolazine in a Model of Doxorubicin-Induced Left Ventricle Diastolic Dysfunction, Br. J. Pharmacol., 174, 3696, 10.1111/bph.13791
Cappetta, 2018, Doxorubicin Targets Multiple Players: A New View of an Old Problem, Pharmacol. Res., 127, 4, 10.1016/j.phrs.2017.03.016
Carvalho, 2010, Metabolic Remodeling Associated with Subchronic Doxorubicin Cardiomyopathy, Toxicology, 270, 92, 10.1016/j.tox.2010.01.019
Chakouri, 2020, Screening for In-Vivo Regional Contractile Defaults to Predict the Delayed Doxorubicin Cardiotoxicity in Juvenile Rat, Theranostics, 10, 8130, 10.7150/thno.47407
Elhadidy, 2020, Effect of Ghrelin on VEGF-B and Connexin-43 in a Rat Model of Doxorubicin-Induced Cardiomyopathy, J. Basic Clin. Physiol. Pharmacol., 31, 1, 10.1515/jbcpp-2018-0212
Ferreira, 2020, Levelling the Translational gap for Animal to Human Efficacy Data, Animals, 10, 1, 10.3390/ani10071199
Forssen, 1981, Use of Anionic Liposomes for the Reduction of Chronic Doxorubicin-Induced Cardiotoxicity, Proc. Natl. Acad. Sci., 78, 1873, 10.1073/pnas.78.3.1873
Gioffré, 2019, Plasmatic and Chamber-specific Modulation of Cardiac microRNAs in an Acute Model of DOX-Induced Cardiotoxicity, Biomed. Pharmacother., 110, 1, 10.1016/j.biopha.2018.11.042
Goormaghtigh, 1980, Evidence of a Specific Complex between Adriamycin and Negatively-Charged Phospholipids, Biochim. Biophys. Acta (Bba)—Biomembranes, 597, 1, 10.1016/0005-2736(80)90145-5
Herman, 1985, Comparison of the Severity of the Chronic Cardiotoxicity Produced by Doxorubicin in Normotensive and Hypertensive Rats, Toxicol. Appl. Pharmacol., 78, 202, 10.1016/0041-008X(85)90284-4
Herman, 1983, Influence of Vitamin E and ICRF-187 on Chronic Doxorubicin Cardiotoxicity in Miniature Swinefluence of Vitamin E and ICRF-187 on Chronic Doxorubicin Cardiotoxicity in Miniature Swine, Lab. Invest., 49, 69
Herman, 1997, Animal Models of Anthracycline Cardiotoxicity: Basic Mechanisms and Cardioprotective Activity, Prog. Pediatr. Cardiol., 8, 49, 10.1016/S1058-9813(98)00002-2
Hole, 2013, A Short-Time Model to Study Relevant Indices of Cardiotoxicity of Doxorubicin in the Rat, Toxicol. Mech. Methods, 23, 412, 10.3109/15376516.2013.773391
Holmberg, 1990, Patterns of Interaction between Anthraquinone Drugs and the Calcium-Release Channel from Cardiac Sarcoplasmic Reticulum, Circ. Res., 67, 272, 10.1161/01.RES.67.2.272
Hu, 2020, Asiatic Acid Protects against Doxorubicin-Induced Cardiotoxicity in Mice, Oxidative Med. Cell Longevity, 2020, 1, 10.1155/2020/5347204
Hullin, 2018, Diverging Effects of Enalapril or Eplerenone in Primary Prevention against Doxorubicin-Induced Cardiotoxicity, Cardiovasc. Res., 114, 272, 10.1093/cvr/cvx162
Hydock, 2012, Rehabilitative Exercise in a Rat Model of Doxorubicin Cardiotoxicity, Exp. Biol. Med. (Maywood), 237, 1483, 10.1258/ebm.2012.012137
Ivanová, 2012, Chronic Cardiotoxicity of Doxorubicin Involves Activation of Myocardial and Circulating Matrix Metalloproteinases in Rats, Acta Pharmacol. Sin, 33, 459, 10.1038/aps.2011.194
Jaenke, 1974, An Anthracycline Antibiotic-Induced Cardiomyopathy in Rabbits, Lab. Invest., 30, 292
Johansen, 1981, Doxorubicin Pharmacokinetics after Intravenous and Intraperitoneal Administration in the Nude Mouse, Cancer Chemother. Pharmacol., 5, 267, 10.1007/BF00434396
Kang, 2017, Avaliação de cardiotoxicidade subclínica induzida por doxorrubicina em um modelo de rato por speckle-tracking, Arq Bras Cardiol., 109, 132, 10.5935/abc.20170097
Kanter, 1985, Effect of Exercise Training on Antioxidant Enzymes and Cardiotoxicity of Doxorubicin, J. Appl. Physiol., 59, 1298, 10.1152/jappl.1985.59.4.1298
Kappus, 1980, In Vivo studies on Adriamycin-Induced Lipid Peroxidation and Effects of Ferrous Ions, Dev. Toxicol. Environ. Sci., 8, 635
Kashfi, 1990, Inhibition of Mitochondrial Carnitine Palmitoyltransferases by Adriamycin and Adriamycin Analogues, Biochem. Pharmacol., 40, 1441, 10.1016/0006-2952(90)90438-Q
Keung, 1991, L-type Cardiac Calcium Channels in Doxorubicin Cardiomyopathy in Rats Morphological, Biochemical, and Functional Correlations, J. Clin. Invest., 87, 2108, 10.1172/JCI115241
Kim, 2019, Understanding of ROS-Inducing Strategy in Anticancer Therapy, Oxid Med. Cel Longev, 1, 10.1155/2019/5381692
Lanza, 1989, The Rat Model in the Comparative Evaluation of Anthracyclines Cardiotoxicity, Tumori, 75, 533, 10.1177/030089168907500603
Li, 2006, Thrombopoietin Protects against In Vitro and In Vivo Cardiotoxicity Induced by Doxorubicin, Circulation, 113, 2211, 10.1161/CIRCULATIONAHA.105.560250
Lipshultz, 2014, Dexrazoxane for Reducing Anthracycline-Related Cardiotoxicity in Children with Cancer: An Update of the Evidence, Prog. Pediatr. Cardiol., 36, 39, 10.1016/j.ppedcard.2014.09.007
Liu, 2007, [Effect of Curcumin on Expression of Survivin, Bcl-2 and Bax in Human Multiple Myeloma Cell Line], Zhongguo Shi Yan Xue Ye Xue Za Zhi, 15, 762
Lončar-Turukalo, 2015, Heart Rate Dynamics in Doxorubicin-Induced Cardiomyopathy, Physiol. Meas., 36, 727, 10.1088/0967-3334/36/4/727
Lüscher, 2000, Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs, Circulation, 102, 2434, 10.1161/01.CIR.102.19.2434
Maral, 1967, [Toxicologic Study and Experimental Antitumor Activity of Rubidomycin (13,057 R.P.)], Pathol. Biol., 15, 903
Markham, 2020, Clinical Cancer Advances 2020: Annual Report on Progress against Cancer from the American Society of Clinical Oncology, Jco, 38, 1081, 10.1200/JCO.19.03141
May, 1980, Solution Chemistry Studies of Adriamycin-Iron Complexes Present In Vivo, Eur. J. Cancer (1965), 16, 1275, 10.1016/0014-2964(80)90189-9
McGowan, 2017, Anthracycline Chemotherapy and Cardiotoxicity, Cardiovasc. Drugs Ther., 31, 63, 10.1007/s10557-016-6711-0
Medeiros-Lima, 2019, Time Course of Cardiomyopathy Induced by Doxorubicin in Rats, Pharmacol. Rep., 71, 583, 10.1016/j.pharep.2019.02.013
Merlet, 2013, Increased Beta2-Adrenoceptors in Doxorubicin-Induced Cardiomyopathy in Rat, PLoS One, 8, e64711, 10.1371/journal.pone.0064711
Mettler, 1977, Adriamycin-induced Cardiotoxicity (Cardiomyopathy and Congestive Heart Failure) in Rats, Cancer Res., 37, 2705
Miller, 1993, Endothelin-Mediated Cardiorenal Hemodynamic and Neuroendocrine Effects Are Attenuated by Nitroglycerin In Vivo, Am. J. Hypertens., 6, 156, 10.1093/ajh/6.2.156
Minotti, 2004, Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity, Pharmacol. Rev., 56, 185, 10.1124/pr.56.2.6
Minotti, 1998, The Secondary Alcohol Metabolite of Doxorubicin Irreversibly Inactivates Aconitase/iron Regulatory Protein‐1 in Cytosolic Fractions from Human Myocardium, FASEB j., 12, 541, 10.1096/fasebj.12.7.541
Mizuta, 2020, Sodium Thiosulfate Prevents Doxorubicin-Induced DNA Damage and Apoptosis in Cardiomyocytes in Mice, Life Sci., 257, 118074, 10.1016/j.lfs.2020.118074
Mollard, 2011, How Can Grafted Breast Cancer Models Be Optimized?, Cancer Biol. Ther., 12, 855, 10.4161/cbt.12.10.18139
Mostafa, 2000, S-allylcysteine Ameliorates Doxorubicin Toxicity in the Heart and Liver in Mice, Planta Med., 66, 148, 10.1055/s-2000-11124
Nakahara, 2018, Rat Model of Cardiotoxic Drug-Induced Cardiomyopathy, Methods Mol. Biol., 1816, 221, 10.1007/978-1-4939-8597-5_17
Naresh, 2020, Cardiac MRI Myocardial Functional and Tissue Characterization Detects Early Cardiac Dysfunction in a Mouse Model of Chemotherapy‐Induced Cardiotoxicity, NMR Biomed., 33, 1, 10.1002/nbm.4327
Nebigil, 2018, Updates in Anthracycline-Mediated Cardiotoxicity, Front. Pharmacol., 9, 1, 10.3389/fphar.2018.01262
Neilan, 2006, Tissue Doppler Imaging Predicts Left Ventricular Dysfunction and Mortality in a Murine Model of Cardiac Injury, Eur. Heart J., 27, 1868, 10.1093/eurheartj/ehl013
Nitobe, 2003, Reactive Oxygen Species Regulate FLICE Inhibitory Protein (FLIP) and Susceptibility to Fas-Mediated Apoptosis in Cardiac Myocytes, Cardiovasc. Res., 57, 119, 10.1016/S0008-6363(02)00646-6
Octavia, 2012, Doxorubicin-induced Cardiomyopathy: From Molecular Mechanisms to Therapeutic Strategies, J. Mol. Cell Cardiol., 52, 1213, 10.1016/j.yjmcc.2012.03.006
Papadopoulou, 1999, Structural and Functional Impairment of Mitochondria in Adriamycin-Induced Cardiomyopathy in Mice: Suppression of Cytochrome C Oxidase II Gene Expression, Biochem. Pharmacol., 57, 481, 10.1016/S0006-2952(98)00305-0
Pei, 2016, S100A8 and S100A9 Are Associated with Doxorubicin-Induced Cardiotoxicity in the Heart of Diabetic Mice, Front. Physiol., 7, 1, 10.3389/fphys.2016.00334
Peres Diaz, 2020, Short-term Doxorubicin Cardiotoxic Effects: Involvement of Cardiac Thyrotropin Releasing Hormone System, Life Sci., 261, 118346, 10.1016/j.lfs.2020.118346
Picard, 1998, Coordinated Upregulation of the Cardiac Endothelin System in a Rat Model of Heart Failure, J. Cardiovasc. Pharmacol., 31, S294, 10.1097/00005344-199800001-00082
Pieske, 1999, Functional Effects of Endothelin and Regulation of Endothelin Receptors in Isolated Human Nonfailing and Failing Myocardium, Circulation, 99, 1802, 10.1161/01.CIR.99.14.1802
Pillai, 2017, Honokiol, an Activator of Sirtuin-3 (SIRT3) Preserves Mitochondria and Protects the Heart from Doxorubicin-Induced Cardiomyopathy in Mice, Oncotarget, 8, 34082, 10.18632/oncotarget.16133
Pound, 2018, Is it Possible to Overcome Issues of External Validity in Preclinical Animal Research? Why Most Animal Models Are Bound to Fail, J. Transl Med., 16, 1, 10.1186/s12967-018-1678-1
Rahimi Balaei, 2010, The Modulatory Effect of Lithium on Doxorubicin-Induced Cardiotoxicity in Rat, Eur. J. Pharmacol., 641, 193, 10.1016/j.ejphar.2010.05.046
Razmaraii, 2016, Cardioprotective Effect of Phenytoin on Doxorubicin-Induced Cardiac Toxicity in a Rat Model, J. Cardiovasc. Pharmacol., 67, 237, 10.1097/FJC.0000000000000339
Renu, 2018, Molecular Mechanism of Doxorubicin-Induced Cardiomyopathy - an Update, Eur. J. Pharmacol., 818, 241, 10.1016/j.ejphar.2017.10.043
Robert, 2007, Preclinical Assessment of Anthracycline Cardiotoxicity in Laboratory Animals: Predictiveness and Pitfalls, Cell Biol Toxicol, 23, 27, 10.1007/s10565-006-0142-9
Sabatino, 2020, Empagliflozin Prevents Doxorubicin-Induced Myocardial Dysfunction, Cardiovasc. Diabetol., 19, 66, 10.1186/s12933-020-01040-5
Sacco, 2001, Cardioprotective Effects of Zofenopril, a New Angiotensin-Converting Enzyme Inhibitor, on Doxorubicin-Induced Cardiotoxicity in the Rat, Eur. J. Pharmacol., 414, 71, 10.1016/S0014-2999(01)00782-8
Saeki, 2002, Doxorubicin Directly Binds to the Cardiac-type Ryanodine Receptor, Life Sci., 70, 2377, 10.1016/S0024-3205(02)01524-2
Sahu, 2016, Baicalein Alleviates Doxorubicin-Induced Cardiotoxicity via Suppression of Myocardial Oxidative Stress and Apoptosis in Mice, Life Sci., 144, 8, 10.1016/j.lfs.2015.11.018
Santos, 2018, Doxorubicin-Induced Cardiotoxicity: From Mechanisms to Development of Efficient Therapy, Cardiotoxicity, 3, 10.5772/intechopen.79588
Sayed-Ahmed, 2001, Increased Plasma Endothelin-1 and Cardiac Nitric Oxide during Doxorubicin-Induced Cardiomyopathy, Pharmacol. Toxicol., 89, 140, 10.1111/j.1600-0773.2001.890305.x10.1034/j.1600-0773.2001.d01-148.x
Schlame, 2000, The Biosynthesis and Functional Role of Cardiolipin, Prog. Lipid Res., 39, 257, 10.1016/S0163-7827(00)00005-9
Sharma, 2020, Modulation of Nrf2 by Quercetin in Doxorubicin-Treated Rats, Heliyon, 6, e03803, 10.1016/j.heliyon.2020.e03803
Simon, 2013, A Comparative Phenotypic and Genomic Analysis of C57BL/6J and C57BL/6N Mouse Strains, Genome Biol., 14, R82, 10.1186/gb-2013-14-7-r82
Suzuki, 2001, A Novel Pharmacological Action of ET-1 to Prevent the Cytotoxicity of Doxorubicin in Cardiomyocytes, Am. J. Physiology-Regulatory, Integr. Comp. Physiol., 280, R1399, 10.1152/ajpregu.2001.280.5.r1399
Toblli, 2014, Ferric Carboxymaltose-Mediated Attenuation of Doxorubicin-Induced Cardiotoxicity in an Iron Deficiency Rat Model, Chemother. Res. Pract., 2014, 1, 10.1155/2014/570241
Todorova, 2012, Transcriptome Profiling of Peripheral Blood Cells Identifies Potential Biomarkers for Doxorubicin Cardiotoxicity in a Rat Model, PLoS One, 7, e48398, 10.1371/journal.pone.0048398
van Acker, 1996, Doxorubicin-induced Cardiotoxicity Monitored by ECG in Freely Moving Mice, Cancer Chemother. Pharmacol., 38, 95, 10.1007/s002800050453
van der Vijgh, 1988, Morphometric Study of Myocardial Changes during Doxorubicin-Induced Cardiomyopathy in Mice, Eur. J. Cancer Clin. Oncol., 24, 1603, 10.1016/0277-5379(88)90052-1
Vandenwijngaert, 2017, Decreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice, Antioxid. Redox Signaling, 26, 153, 10.1089/ars.2015.6542
Varela-López, 2019, An Update on the Mechanisms Related to Cell Death and Toxicity of Doxorubicin and the Protective Role of Nutrients, Food Chem. Toxicol., 134, 110834, 10.1016/j.fct.2019.110834
Vedam, 2010, Role of Heat Shock Factor-1 Activation in the Doxorubicin-Induced Heart Failure in Mice, Am. J. Physiology-Heart Circulatory Physiol., 298, H1832, 10.1152/ajpheart.01047.2009
Ventura-Clapier, 2004, Energy Metabolism in Heart Failure, J. Physiol., 555, 1, 10.1113/jphysiol.2003.055095
Villani, 1991, Prevention of Doxorubicin-Induced Cardiomyopathy by Reduced Glutathione, Cancer Chemother. Pharmacol., 28, 365, 10.1007/BF00685691
Vincent, 2013, The Role of Antioxidants in the Era of Cardio-Oncology, Cancer Chemother. Pharmacol., 72, 1157, 10.1007/s00280-013-2260-4
Wallace, 2020, Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy, Circ. Res., 126, 926, 10.1161/CIRCRESAHA.119.314681
Wang, 2019, SESN2 Protects against Doxorubicin-Induced Cardiomyopathy via Rescuing Mitophagy and Improving Mitochondrial Function, J. Mol. Cell Cardiol., 133, 125, 10.1016/j.yjmcc.2019.06.005
Weidemann, 2006, Detection of Subclinical LV Dysfunction by Tissue Doppler Imaging, Eur. Heart J., 27, 1771, 10.1093/eurheartj/ehl144
Xu, 2005, Molecular Pharmacology of the Interaction of Anthracyclines with Iron, Mol. Pharmacol., 68, 261, 10.1124/mol.105.013383
Xujie, 2012, C57BL/6 Mice Are More Appropriate Than BALB/C Mice in Inducing Dilated Cardiomyopathy with Short-Term Doxorubicin Treatment, Acta Cardiol. Sin, 28, 236240
Ye, 2020, Interleukin-9 Aggravates Doxorubicin-Induced Cardiotoxicity by Promoting Inflammation and Apoptosis in Mice, Life Sci., 255, 117844, 10.1016/j.lfs.2020.117844
Zamorano, 2016, 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed under the Auspices of the ESC Committee for Practice Guidelines, Eur. Heart J., 37, 2768, 10.1093/eurheartj/ehw211
Zbinden, 1978, Model Systems for Cardiotoxic Effects of Anthracyclines, Antibiot. Chemother., 23, 255, 10.1159/000401489